Scheduled Maintenance Notice
Please note that Researcher Profiles will be undergoing scheduled maintenance on Wednesday 7th Oct, from 8:00am to 9:00am. During this time, the Researcher Profiles system will be unavailable. We apologise for any inconvenience and appreciate your understanding.
Select Publications
Conference Papers
, 2024, 'NEUROINFLAMMATION DRIVES ACUTE LYMPHOBLASTIC LEUKEMIA THERAPY-INDUCED NEUROPATHY', in JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, WILEY, CANADA, Montreal, pp. S77 - S78, presented at Annual Meeting of the Peripheral-Nerve-Society (PNS), CANADA, Montreal, 22 June 2024 - 25 June 2024
, 2024, 'Zero Childhood Cancer National Precision Medicine Program: Improving outcomes for children with high risk cancer cancer utilising comprehensive, integrated multiomic profiling', in EUROPEAN JOURNAL OF HUMAN GENETICS, SPRINGERNATURE, GERMANY, Berlin, pp. 800 - 800, presented at 57th Conference of the European-Society-of-Human-Genetics (ESHG), GERMANY, Berlin, 01 June 2024 - 04 June 2024
, 2023, 'STAT5 ACTIVATION PROMOTES PROGRESSION AND CHEMOTHERAPY-RESISTANCE IN EARLY T-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA', in EXPERIMENTAL HEMATOLOGY, ELSEVIER SCIENCE INC, NY, New York, pp. S151 - S151, presented at 52nd Annual Meeting of the International-Society-for-Experimental-Hematology (ISEH), NY, New York, 17 August 2023 - 20 August 2023
, 2022, 'Establishment and application of patient-derived xenograft models for personalised medicine in paediatric cancer', Sydney, presented at Children’s Cancer Institute - Research Symposium 2022, Sydney, 06 December 2022
, 2022, 'MULTI-PLATFORM TYROSINE KINASE PROFILING REVEALS NOVEL ACTIONABLE FGFR ABERRATIONS ACROSS PEDIATRIC AND ADOLESCENT AND YOUNG ADULT SARCOMAS', Vancouver, Canada, presented at Connective Tissue Oncology Society (CTOS) Annual Meeting 2022, Vancouver, Canada, 17 November 2022
, 2022, 'Pediatric Preclinical Testing Consortium Evaluation of the Anti-CD123 Antibody-Drug Conjugate, IMGN632, Against Patient-Derived Xenograft Models of Pediatric Acute Lymphoblastic Leukemia', in Blood, American Society of Hematology, pp. 8983 - 8984, http://dx.doi.org/10.1182/blood-2022-159867
, 2022, 'Pediatric Preclinical Testing Consortium Evaluation of the MCL1 Inhibitor, AMG 176, Against Xenograft Models of Acute Lymphoblastic Leukemia', in Blood, American Society of Hematology, pp. 11690 - 11691, http://dx.doi.org/10.1182/blood-2022-159885
, 2021, 'Abstract P143: Development of siRNA-loaded lipid nanoparticles targeting long non-coding RNA LINC01257 as a novel and safe therapeutic approach for paediatric acute myeloid leukaemia', in Molecular Cancer Therapeutics, American Association for Cancer Research (AACR), pp. p143 - p143, http://dx.doi.org/10.1158/1535-7163.targ-21-p143
, 2021, 'Multi-platform tyrosine kinase profiling reveals novel molecular response signatures to FGFR-inhibitors in paediatric and AYA sarcoma', Sydney (virtual), presented at Kids Cancer Alliance (KCA) Symposium 2021, Sydney (virtual), 02 September 2021
, 2021, 'Abstract 3038: Evaluation of ROR1-targeted antibody-drug conjugates against ROR1-expressing pediatric preclinical models - a report from the pediatric preclinical testing consortium (PPTC)', in Cancer Research, American Association for Cancer Research (AACR), pp. 3038 - 3038, http://dx.doi.org/10.1158/1538-7445.am2021-3038
, 2021, 'Abstract 3039: Pediatric preclinical testing consortium evaluation of the dual SYK/FLT3 inhibitor TAK-659 in xenograft models of pediatric acute lymphoblastic leukemia', in Cancer Research, American Association for Cancer Research (AACR), pp. 3039 - 3039, http://dx.doi.org/10.1158/1538-7445.am2021-3039
, 2021, 'Abstract LB171: The differentiated CD47 monoclonal antibody AO-176 exhibits significant in vivo activity against xenograft models of pediatric acute lymphoblastic leukemia (ALL)', in Cancer Research, American Association for Cancer Research (AACR), pp. lb171 - lb171, http://dx.doi.org/10.1158/1538-7445.am2021-lb171
, 2021, 'Supporting clinical decision-making for PI3K/AKT/mTOR inhibitors for high-risk paediatric and adolescent and young adult (AYA) sarcoma', Virtual, presented at The Australian and New Zealand Children’s Haematology/Oncology Group (ANZCHOG) Annual Scientific Meeting, Virtual, 24 June 2021
, 2021, 'Multi-platform tyrosine kinase profiling reveals novel molecular response signatures to FGFR-inhibitors in paediatric and AYA sarcoma.', Virtual, presented at The Australian Society for Medical Research (ASMR) 2021, Virtual, 10 June 2021
, 2020, 'Supporting clinical decision-making for PI3K/AKT/MTOR inhibitors for high-risk paediatric and AYA sarcoma', Virtual, presented at Connective Tissue Oncology Society (CTOS) Annual Meeting 2020, Virtual, 18 November 2020
, 2020, 'Supporting clinical decision-making for PI3K/AKT/MTOR inhibitors for high-risk paediatric sarcoma patients', Virtual, presented at KCA Symposium 2020, Virtual, 17 September 2020
, 2020, 'Abstract 4181: The XPO1 inhibitior, eltanexor, exhibits potent in vivo activity against a broad range of pediatric acute lymphoblastic leukemia subtypes', in Cancer Research, American Association for Cancer Research (AACR), pp. 4181 - 4181, http://dx.doi.org/10.1158/1538-7445.am2020-4181
, 2020, 'Abstract IA13: Molecular targeted therapies and precision medicine for children with neuroblastoma and other refractory malignancies', in Cancer Research, American Association for Cancer Research (AACR), pp. ia13 - ia13, http://dx.doi.org/10.1158/1538-7445.pedca19-ia13
, 2020, 'Precision medicine for high-risk paediatric and AYA sarcomas', Lorne, presented at Lorne Cancer 2020, Lorne, 13 February 2020
, 2019, 'Abstract A123: Reversal of glucocorticoid resistance in pediatric acute lymphoblastic leukemia is dependent on restoring BIM expression', in Molecular Cancer Therapeutics, American Association for Cancer Research (AACR), pp. a123 - a123, http://dx.doi.org/10.1158/1535-7163.targ-19-a123
, 2019, 'Abstract C004: The CXCR4 inhibitor X4-136 enhances the in vivo efficacy of established drugs against preclinical models of aggressive pediatric acute lymphoblastic leukemia', in Molecular Cancer Therapeutics, American Association for Cancer Research (AACR), pp. c004 - c004, http://dx.doi.org/10.1158/1535-7163.targ-19-c004
, 2019, 'Personalised medicine for high-risk paediatric and AYA sarcoma patients', Tokyo, Japan, presented at Connective Tissue Oncology Society (CTOS) Annual Meeting, Tokyo, Japan, 13 November 2019, https://www.ctos.org/Portals/0/PDF/2019%20CTOS%20Final%20Program.pdf
, 2019, 'A Gain of Function Mutation in the NSD2 Histone Methyltransferase Drives Glucocorticoid Resistance Via Blocking Receptor Auto-Induction and BIM/Bmf Expression in ALL', in Blood, American Society of Hematology, pp. 3758, http://dx.doi.org/10.1182/blood-2019-126910
, 2019, 'Pediatric Preclinical Testing Consortium Evaluation of the Novel Anti-Microtubule Drug E7130 in Xenograft Models of Early T-Cell Precursor Acute Lymphoblastic Leukemia', in Blood, American Society of Hematology, pp. 3875, http://dx.doi.org/10.1182/blood-2019-123867
, 2019, 'Precision medicine for high-risk paediatric and AYA sarcomas', Sydney, presented at Kids Cancer Alliance - Annual Meeting, Sydney, 31 October 2019, https://kca.org.au/wp-content/uploads/2019/11/2019-ECR-and-Student-Event-Program.pdf
, 2019, 'Abstract 3839: Comparison of thio-deoxy-cytidine (TdCyd) and aza-thio-deoxy-cytidine (Aza-TdCyd) in solid and liquid tumor cell lines and PPTC pediatric xenografts', in Cancer Research, American Association for Cancer Research (AACR), pp. 3839 - 3839, http://dx.doi.org/10.1158/1538-7445.am2019-3839
, 2019, 'Abstract LB-321: Re-evaluating sample sizes in preclinical testing of patient-derived xenografts', in Cancer Research, American Association for Cancer Research (AACR), pp. lb-321-lb-321, http://dx.doi.org/10.1158/1538-7445.am2019-lb-321
, 2019, 'Abstract LB-321: Re-evaluating sample sizes in preclinical testing of patient-derived xenografts', American Association for Cancer Research (AACR), pp. lb-321-lb-321, presented at Tumor Biology, http://dx.doi.org/10.1158/1538-7445.sabcs18-lb-321
, 2018, 'A Single Mouse Trial Platform for Evaluation of Novel Agents in Acute Lymphoblastic Leukemia By the Pediatric Preclinical Testing Consortium', in Blood, American Society of Hematology, pp. 4010, http://dx.doi.org/10.1182/blood-2018-99-113207
, 2018, 'Abstract 3173: Lymphocyte-specific chromatin accessibility predetermines glucocorticoid resistance in acute lymphoblastic leukemia', in Cancer Research, American Association for Cancer Research (AACR), pp. 3173 - 3173, http://dx.doi.org/10.1158/1538-7445.am2018-3173
, 2018, 'Abstract 3187: Pediatric Preclinical Testing Consortium evaluation of the menin inhibitor, VTP-50469, against xenograft models of MLL-rearranged infant acute lymphoblastic leukemia', in Cancer Research, American Association for Cancer Research (AACR), pp. 3187 - 3187, http://dx.doi.org/10.1158/1538-7445.am2018-3187
, 2018, 'Abstract LB-B12: Pediatric Preclinical Testing Consortium evaluation of 4’-thio-2’-deoxycytidine (TdCyd) and 5-aza-4’-thio-2’-deoxycytidine (Aza-TdCyd)', in Molecular Cancer Therapeutics, American Association for Cancer Research (AACR), pp. lb-b12-lb-b12, http://dx.doi.org/10.1158/1535-7163.targ-17-lb-b12
, 2018, 'Abstract LB-B14: Pediatric Preclinical Testing Consortium evaluation of the second-generation selective inhibitor of nuclear export (SINE) compound KPT-8602', in Molecular Cancer Therapeutics, American Association for Cancer Research (AACR), pp. lb-b14-lb-b14, http://dx.doi.org/10.1158/1535-7163.targ-17-lb-b14
, 2018, 'Abstract LB-B16: The AKR1C3-Activated Prodrug OBI-3424 Exerts Profound In Vivo Efficacy Against Preclinical Models of T-Cell Acute Lymphoblastic Leukemia (T-ALL); a Pediatric Preclinical Testing Consortium Study', in Molecular Cancer Therapeutics, American Association for Cancer Research (AACR), pp. lb-b16-lb-b16, http://dx.doi.org/10.1158/1535-7163.targ-17-lb-b16
, 2017, 'The use of Murine Models of Chemosensitivity to Anticancer Agents in Childhood Cancer Clinical Care: Survivor, Parent and Community Acceptability and Willingness-to-Pay', in PEDIATRIC BLOOD & CANCER, WILEY, pp. S60 - S61, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000408978201113&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2017, 'Abstract 1175: Inhibition of NAMPT as a novel therapeutic strategy for infant leukemia', in Cancer Research, American Association for Cancer Research (AACR), pp. 1175 - 1175, http://dx.doi.org/10.1158/1538-7445.am2017-1175
, 2017, 'Abstract 1942: The nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, OT-82, exhibits in vitro and in vivo efficacy against patient-derived xenograft models of high-risk acute lymphoblastic leukemia', in Cancer Research, American Association for Cancer Research (AACR), pp. 1942 - 1942, http://dx.doi.org/10.1158/1538-7445.am2017-1942
, 2015, 'Investigation of a Novel Cyclin-Dependent-Kinase (CDK) Inhibitor Cdki-73 As an Effective Treatment Option for MLL-AML', in Blood, American Society of Hematology, pp. 1365, http://dx.doi.org/10.1182/blood.v126.23.1365.1365
, 2015, 'Abstract 1616: Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): a report from the Pediatric Preclinical Testing Program', in Cancer Research, American Association for Cancer Research (AACR), pp. 1616 - 1616, http://dx.doi.org/10.1158/1538-7445.am2015-1616
, 2015, 'Abstract 1620: In vivo and in vitro efficacy of birinapant in preclinical models of Ph-like pediatric acute lymphoblastic leukemia', in Cancer Research, American Association for Cancer Research (AACR), pp. 1620 - 1620, http://dx.doi.org/10.1158/1538-7445.am2015-1620
, 2015, 'Abstract 1631: Bioluminescence imaging enhances analysis of drug response in a patient-derived xenograft model of pediatric acute lymphoblastic leukemia', in Cancer Research, American Association for Cancer Research (AACR), pp. 1631 - 1631, http://dx.doi.org/10.1158/1538-7445.am2015-1631
, 2015, 'Abstract 1615: Initial testing (stage 1) of the Curaxin, CBL0137, by the Pediatric Preclinical Testing Program (PPTP)', in Cancer Research, American Association for Cancer Research (AACR), PA, Philadelphia, pp. 1615 - 1615, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.am2015-1615
, 2014, '5-Aza-2′-Deoxycytidine Promotes Cytotoxic Effect of CART-Cells on Leukaemia Cells', in Blood, American Society of Hematology, pp. 5812, http://dx.doi.org/10.1182/blood.v124.21.5812.5812
, 2014, 'EARLY T-CELL PRECURSOR (ETP) ACUTE LYMPHOBLASTIC LEUKEMIA IS CHARACTERIZED BY ABERRANT ACTIVATION OF THE JAK/STAT PATHWAY AND PROFOUND RESPONSES TO RUXOLITINIB IN XENOGRAFT MODELS', in PEDIATRIC BLOOD & CANCER, WILEY-BLACKWELL, pp. S109 - S109, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000343932100014&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2014, 'Abstract B26: Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts', in Cancer Research, American Association for Cancer Research (AACR), pp. b26 - b26, http://dx.doi.org/10.1158/1538-7445.pedcan-b26
, 2014, '410 Pediatric Preclinical Testing Program (PPTP) Evaluation of the p53-MDM2 Antagonist MK-8242', in European Journal of Cancer, Elsevier, pp. 131, http://dx.doi.org/10.1016/s0959-8049(14)70536-2
, 2014, '412 The Pediatric Preclinical Testing Program (PPTP): Analysis of the first 10 years in vivo testing', in European Journal of Cancer, Elsevier, pp. 131 - 132, http://dx.doi.org/10.1016/s0959-8049(14)70538-6
, 2013, 'Effective Targeting Of The P53/MDM2 Axis In Preclinical Models Of Infant MLL-Rearranged Acute Lymphoblastic Leukemia', in Blood, American Society of Hematology, pp. 71, http://dx.doi.org/10.1182/blood.v122.21.71.71
, 2013, 'The selective targeting of cell survival pathways in leukemia', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/1538-7445.FBCR13-A19
, 2013, 'BET bromodomain inhibition as a therapeutic strategy to target N-Myc in neuroblastoma', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, NETHERLANDS, Amsterdam, pp. S356 - S356, presented at European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, NETHERLANDS, Amsterdam, 27 September 2013 - 01 October 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000326843602301&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1